|Systematic (IUPAC) name|
5-EAPB (1-(benzofuran-5-yl)-N-ethylpropan-2-amine) is an entactogenic amphetamine which is structurally related to 5-MAPB and 5-APB. It might be predicted to show similar effects to these drugs in humans, but the pharmacology of 5-EAPB remains unstudied as of 2013.
5-EAPB is similar in structure to compounds such as 5-APB which are claimed to be agonists of the 5-HT2C receptor  as well as a triple monoamine reuptake inhibitors, however 5-EAPB is not listed as an example in this patent, and it is not yet established to what extent the activity of 5-EAPB resembles that of 5-APB.
As an N-ethyl derivative of 5-APB, 5-EAPB falls outside the scope of the Temporary Class Drug ban issued by the Home Office on June 10, 2013, and remains uncontrolled in the UK as of November 2013. The ACMD has advised that 5-EAPB (and other -APBs) are moved to Class B, this will likely come into action on 10th June 2014.
Adverse reactions and deaths
Three people in their 30s were hospitalised after each taking approximately 500 mg of 5-EAPB, one of whom later died in hospital, whilst attending Brownstock music festival in Essex, UK on August 31, 2013.
- US patent 7045545, Karin Briner et al, "Aminoalkylbenzofurans as serotonin (5-HT(2c)) agonists", published 2000-01-19, issued 2006-16-03
- "Temporary class drug order report on 5-6APB and NBOMe compounds". UK Home Office. 4 Jun 2013. Retrieved 2013-07-10.
- Festivalgoer's death prompts drug warning. The Guardian, 1 September 2013